LEGN
vs
S&P 500
LEGN
S&P 500
Over the past 12 months, LEGN has underperformed S&P 500, delivering a return of -34% compared to the S&P 500's +14% growth.
Stocks Performance
LEGN vs S&P 500
Performance Gap
LEGN vs S&P 500
Performance By Year
LEGN vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Legend Biotech Corp
Glance View
Legend Biotech Corp., an emerging leader in the biotechnology arena, has carved out a niche at the forefront of cellular therapeutics, focusing on transforming cancer treatment paradigms. Born out of the ambition to explore innovative medical frontiers, Legend Biotech embarked on a mission to develop Car-T cell therapies—a personalized form of immunotherapy that employs genetically altered T-cells to target and eradicate cancer cells. With its signature product, Carvykti (ciltacabtagene autoleucel), Legend Biotech has been making waves in the oncology sector. By redirecting the body's own immune system against multiple myeloma, a rare and challenging form of cancer, the company has demonstrated the potential to achieve deep and lasting remissions, bringing hope where conventional treatments may fall short. The financial model of Legend Biotech is driven by strategic partnerships, extensive research and development initiatives, and successful navigation through complex regulatory landscapes. Partnering with Johnson & Johnson's subsidiary Janssen Biotech, the collaboration capitalizes on their combined expertise to advance Car-T technology. Revenues primarily flow from milestone payments upon achieving specific developmental goals, along with royalties derived from global sales of their breakthrough treatments. By investing heavily in R&D and ensuring a robust pipeline of therapeutic candidates, Legend Biotech positions itself for sustainable growth, striving to extend their innovative treatments to a broader range of cancers and, eventually, achieve profitability through expanded indications and market reach.
